Search

Your search keyword '"Hariklia Kranidioti"' showing total 21 results
Start Over Author "Hariklia Kranidioti" Topic hepatology
21 results on '"Hariklia Kranidioti"'

1. Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF)

Author

George Papatheodoridis, Konstantinos Mimidis, Spilios Manolakopoulos, Nikolaos Gatselis, Ioannis Goulis, Andreas Kapatais, Emmanouil Manesis, Themistoklis Vasileiadis, Christos Triantos, Demetrious N. Samonakis, Vasilis Sevastianos, Stylianos Karapatanis, Ioannis Elefsiniotis, Melanie Deutsch, Theodora Mylopoulou, Margarita Papatheodoridi, Hariklia Kranidioti, Polyxeni Agorastou, Theofanie Karaoulani, Anastasia Kyriazidou, Konstanitnos Zisimopoulos, and George Dalekos

Subjects
Hepatology
Published
2022
Full Text
View/download PDF

2. A typical autoimmune hepatitis (AIH) case following Covid‐19 mRNA vaccination. More than a coincidence?

Author

Anestis Goulas, Spilios Manolakopoulos, Hariklia Kranidioti, and Georgia Kafiri

Subjects
2019-20 coronavirus outbreak, Hepatology, Medication history, Coronavirus disease 2019 (COVID-19), SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Vaccination, COVID-19, Alcohol abuse, Autoimmune hepatitis, medicine.disease, Hepatitis, Autoimmune, Immunology, Humans, Medicine, RNA, Messenger, business, Autoantibodies
Abstract

Recently in the Liver International, three patients1,2 with AIH during COVID-19 were reported. Τhere is also increasing evidence that vaccination for SARS-CoV-2 may induce autoimmunity3,4 . Here, we present a case of histologically confirmed AIH after mRNA vaccination against SARS-CoV-2. A 52-years-old Caucasian woman with no medication history or alcohol abuse and normal liver blood tests during previous periodical checkup, received her 1st dose of the Moderna vaccine on 11th of May 2021.

Published
2021
Full Text
View/download PDF

3. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues

Author

Spilios Manolakopoulos, Hariklia Kranidioti, Emanuel K. Manesis, Christos Triantos, Anastasia Kourikou, Chrysostomos Tsolias, Nicoletta Mathou, Emilia Hadziyannis, George V. Papatheodoridis, Alexandra Alexopoulou, and Melanie‐Maria Deutsch

Subjects
HBsAg, medicine.medical_specialty, Hepatitis B virus, Gastroenterology, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Hepatitis B, Chronic, Chronic hepatitis, Recurrence, Internal medicine, medicine, Humans, Hepatitis B e Antigens, Prospective Studies, Prospective cohort study, Hepatitis B Surface Antigens, Hepatology, business.industry, Entecavir, medicine.disease, digestive system diseases, Discontinuation, Treatment Outcome, Hbeag negative, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Biochemical relapse, Neoplasm Recurrence, Local, business, medicine.drug, Follow-Up Studies
Abstract

BACKGROUND & AIMS Discontinuation of nucleos(t)ide analogues (NA) remains a debatable issue in HBeAg-negative chronic hepatitis B (CHB). This study aimed to address the outcome of HBeAg-negative CHB patients who discontinued NA therapy. METHODS This prospective study included 57 non-cirrhotic HBeAg-negative Caucasian CHB patients who discontinued NA therapy after median virological remission of 6 years. All patients had regular blood tests. Virological relapse was defined as HBV DNA > 2000 IU/mL or >20 000 IU/mL and biochemical relapse as ALT > ULN (40 IU/mL) or >2xULN. All patients with retreatment predefined criteria restarted entecavir or tenofovir. RESULTS Of the 57 patients, 29 remained without retreatment after median follow-up of 65 months (range: 36-87) following treatment discontinuation. At 3, 6, 12, 24, 36 and 48 months, cumulative rates of retreatment were 16%, 20%, 32%, 35%, 46% and 50%, while the proportion of patients with HBV DNA

Published
2020

4. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B

Author

Melanie Deutsch, Athanasia Striki, Anastasia Kourikou, George V. Papatheodoridis, Emilia Hadziyannis, George Kontos, Hariklia Kranidioti, and Spilios Manolakopoulos

Subjects
Adult, Male, 0301 basic medicine, Hepatitis B virus, medicine.medical_specialty, HBsAg, Antiviral Agents, Gastroenterology, 03 medical and health sciences, Hepatitis B, Chronic, 0302 clinical medicine, Antigen, Telbivudine, Internal medicine, medicine, Adefovir, Humans, Hepatitis B e Antigens, Aged, Proportional Hazards Models, Hepatitis B Surface Antigens, Hepatology, business.industry, virus diseases, Lamivudine, Entecavir, Middle Aged, Hepatitis B, medicine.disease, Virology, digestive system diseases, Kinetics, 030104 developmental biology, HBeAg, DNA, Viral, Female, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

BACKGROUND/AIMS Serum hepatitis B s antigen (HBsAg) levels might be used as a predictor of virological breakthrough or of sustained off-treatment virological response in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11 and telbivudine: 16) and 86 HBeAg-negative CHB patients treated under entecavir or tenofovir for a mean of 30 months as the comparison group. RESULTS Compared to baseline, HBsAg levels decreased by a median of 162, 1525, 943, 1545, 2163 and 3859 IU/mL at 6, 12, 24, 36, 48 and 60 months of therapy with low-genetic barrier NA(s) respectively. The 6-, 12-, 24-, 36-, 48- and 60-month cumulative rates of HBsAg

Published
2017
Full Text
View/download PDF

5. Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF)

Author

George Papatheodoridis, Konstantinos Mimidis, Spilios Manolakopoulos, Nikolaos Gatselis, Ioannis Goulis, ANDREAS Kapatais, Emmanouil Manesis, Themistoklis Vasileiadis, Christos Triantos, Demetrious N. Samonakis, Vasilis Sevastianos, Stylianos Karapatanis, Ioannis Elefsiniotis, Melanie Deutsch, Theodora Mylopoulou, Margarita Papatheodoridi, Hariklia Kranidioti, Polyxeni Agorastou, Theofanie Karaoulani, Anastasia Kyriazidou, Konstanitnos Zisimopoulos, and George Dalekos

Subjects
Hepatology
Published
2020
Full Text
View/download PDF

6. Sa325 THE EFFECT OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY ON THE QUALITY OF LIFE (QOL) OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) WHO ATTEND OPIOID SUBSTITUTION (OST) PROGRAMS IN GREECE

Author

Olga Anagnostou, Charalampos Karageorgos, Hariklia Kranidioti, Sofia Vasileiadi, Panagiotis Fylaktos, Pinelopi Antonakaki, Melanie Deutsch, Asimina Mpougioukli, and Spilios Manolakopoulos

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Internal medicine, Gastroenterology, medicine, Opioid Substitution, business, Direct acting
Published
2021
Full Text
View/download PDF

8. Sa314 PREDICTORS OF LIVER STIFFNESS CHANGES IN CHRONIC HEPATITIS B (CHB) PATIENTS UNDER LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

Author

Christos Triantos, Theodoros Voulgaris, Pinelopi Antonakaki, Melanie Deutsch, Chrisostomos Tsolias, Hariklia Kranidioti, John Goulis, Adonis A. Protopapas, George V. Papatheodoridis, and Spilios Manolakopoulos

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, Chronic hepatitis, business.industry, Liver stiffness, Internal medicine, Gastroenterology, Medicine, Long term therapy, business, medicine.drug
Published
2021
Full Text
View/download PDF

9. Sa323 HCV REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRAL THERAPY (DAA) IN PEOPLE WHO INJECT DRUGS (PWID)

Author

Marina Patsi, Olga Anagnostou, Panagiotis Fylaktos, Melanie Deutsch, Hariklia Kranidioti, Kanellos-Rafail Koustenis, Evangelia Koutli, Sofia Vasileiadi, Spilios Manolakopoulos, and Pinelopi Antonakaki

Subjects
Hepatology, business.industry, Gastroenterology, Antiviral therapy, Medicine, business, Virology, Direct acting
Published
2021
Full Text
View/download PDF

10. Sa1521 LONG-TERM OUTCOME IN NON-CIRRHOTIC PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB) WHO STOPPED ENTECAVIR (ETV) OR TENOFOVIR (TDF) THERAPY. FINAL RESULTS OF A MULTICENTER PROSPECTIVE STUDY

Author

Spilios Manolakopoulos, Emanuel K. Manesis, Anastasia Kourikou, Emilia Hadziyannis, Melanie Deutsch, George V. Papatheodoridis, Christos Triantos, Hariklia Kranidioti, Alexandra Alexopoulou, and Nikoletta Mathou

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Gastroenterology, Entecavir, Chronic hepatitis, Hbeag negative, Internal medicine, medicine, business, Prospective cohort study, medicine.drug
Published
2020
Full Text
View/download PDF

11. Sa1524 FACTORS THAT MAY AFFECT THE CHANGES OF LIVER STIFFNESS MEASUREMENTS ASSESSED BY TRANSIENT ELASTOGRAPHY (TE) IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON LONG-TERM THERAPY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

Author

George V. Papatheodoridis, Adonis A. Protopapas, Melanie Deutsch, Theodoros Voulgaris, Hariklia Kranidioti, John Goulis, Christos Triantos, Chrisostomos Tsolias, Spilios Manolakopoulos, Ioanna Segkou, and Pinelopi Antonakaki

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Gastroenterology, Affect (psychology), Chronic hepatitis, Liver stiffness, Internal medicine, medicine, In patient, Long term therapy, business, Transient elastography, medicine.drug
Published
2020
Full Text
View/download PDF

12. SAT-004-Bacterial translocation in patients with liver cirrhosis and variceal bleeding

Author

Christos Triantos, Maria Kalafateli, C. Gogos, Panagiota I. Spantidea, Ioanna Aggeletopoulou, Georgios Tsiaousis, Hariklia Kranidioti, Konstantinos Thomopoulos, Dimitris Goukos, George L. Daikos, Aikaterini Mantaka, Spilios Manolakopoulos, Athanasia Mouzaki, Maria Rodi, Katerina Karaivazoglou, Demetrious Samonakis, and Stylianos Asimakopoulos

Subjects
medicine.medical_specialty, Variceal bleeding, Cirrhosis, Hepatology, business.industry, Internal medicine, medicine, In patient, Bacterial translocation, medicine.disease, business, Gastroenterology
Published
2019
Full Text
View/download PDF

13. Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals: a 9-year Greek cohort study

Author

Spilios Manolakopoulos, V. Papastergiou, George V. Papatheodoridis, Olga Anagnostou, M. Mela, Christos Triantos, Melanie Deutsch, Konstantinos Zisimopoulos, Hariklia Kranidioti, and C. Chatzievangelinou

Subjects
Hepatology, business.industry, Hepatitis C virus, Medicine, business, DIRECT ACTING ANTIVIRALS, medicine.disease_cause, Virology, Cohort study
Published
2018
Full Text
View/download PDF

14. Tu1478 – Rest-B Study: Liver Fibrosis Regression Assessed by Transient Elastography (TE) in Patients with Chronic Hepatitis B (CHB) on Long Term Maintenance Therapy with Tenofovir Disoproxil Fumarate (TDF)

Author

George V. Papatheodoridis, Melanie Deutsch, Christos Triantos, Theodoros Voulgaris, Hariklia Kranidioti, Spilios Manolakopoulos, Kanellos-Rafail Koustenis, Chrisostomos Tsolias, Adonis A. Protopapas, and John Goulis

Subjects
medicine.medical_specialty, Hepatology, Tenofovir, business.industry, Liver fibrosis, Gastroenterology, Long term maintenance, Chronic hepatitis, Internal medicine, Medicine, In patient, business, Transient elastography, Rest (music), medicine.drug
Published
2019
Full Text
View/download PDF

15. Tu1506 – Adherence to Follow-Up of People Who Inject Drugs (PWID) After the Successful Treatment of Chronic Hepatitis C with Direct-Acting Antivirals (DAA)

Author

Hariklia Kranidioti, Kanellos-Rafail Koustenis, Spilios Manolakopoulos, Olga Anagnostou, Melanie Deutsch, Pinelopi Antonakaki, Evangelia Koutli, and Paris Pantsas

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Gastroenterology, medicine, Intensive care medicine, business, DIRECT ACTING ANTIVIRALS
Published
2019
Full Text
View/download PDF

16. Comorbidities in chronic hepatitis B patients currently treated with nucleos(t)ide analogues

Author

Christos Triantos, Spilios Manolakopoulos, G.N. Dalekos, Konstantinos Zisimopoulos, Hariklia Kranidioti, Spyros I. Siakavellas, George V. Papatheodoridis, E. Tsentemidou, Z. Kalliopi, Christos Tsoulas, and Ioannis Goulis

Subjects
medicine.medical_specialty, Hepatology, Chronic hepatitis, business.industry, Internal medicine, Medicine, business, Gastroenterology
Published
2018
Full Text
View/download PDF

18. 481 THE USEFULNESS OF TRANSIENT ELASTOGRAPHY (TE) IN THE ACCURATE ASSESSMENT OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HBV INFECTION (CHBVE-)

Author

A. Katoglou, Georgios Papatheodoridis, Maria-Vasiliki Papageorgiou, Melanie Deutsch, Hariklia Kranidioti, Spilios Manolakopoulos, G. Kontos, E. Pantelidaki, Aikaterini Margariti, and Georgia Kafiri

Subjects
medicine.medical_specialty, Hepatology, Hbeag negative, business.industry, Internal medicine, medicine, Transient elastography, business, Gastroenterology
Published
2012
Full Text
View/download PDF

20. Su1018 Discontinuation of Long-Term Nucleos(T)Ide Analogue(S) [Na(S)] Therapy in HBeAg-Negative Chronic Hepatitis B (Chbe-) Patients Without Cirrhosis: A Prospective Study

Author

Spilios Manolakopoulos, Hariklia Kranidioti, Melanie Deutsch, Alexandra Alexopoulou, Anastasia Kourikou, Georgios A. Kontos, Emilia Hadziyannis, and George V. Papatheodoridis

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Gastroenterology, medicine.disease, Discontinuation, Hbeag negative, Chronic hepatitis, Internal medicine, medicine, business, Prospective cohort study
Published
2014
Full Text
View/download PDF

21. 1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS

Author

Spilios Manolakopoulos, D. Margaritopoulos, Georgios Papatheodoridis, Hariklia Kranidioti, E. Tsirogianni, Dimitrios G. Pectasides, John Goulis, S. Karatapanis, Olga Anagnostou, and Melanie Deutsch

Subjects
Virological response, Hepatology, Intravenous drug, business.industry, Hepatitis C virus, medicine, medicine.disease_cause, business, Virology
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results